Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neodolpasse
- Development stage
- Unknown
- Lead developer
- Fresenius Kabi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Neodolpasse is a fixed-dose combination infusion solution containing the nonsteroidal anti-inflammatory drug (NSAID) diclofenac and the centrally acting muscle relaxant orphenadrine. Developed and manufactured by Fresenius Kabi, it is indicated for the short-term treatment of acute pain syndromes, including postoperative pain and acute vertebrogenic pain. Diclofenac provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Orphenadrine reduces muscle tension associated with pain through its action as a non-competitive NMDA receptor antagonist and has additional antihistaminic and anticholinergic properties. The Medical University of Vienna has investigated its efficacy in patients undergoing elective cruciate ligament surgery to assess its analgesic properties compared to diclofenac monotherapy.
- Brand names
- Neodolpasse
- Other names
- diclofenac + orphenadrinediclofenac sodium + orphenadrine citrate
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Neodolpasse.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neodolpasse.